Succesful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group

L. P. Miller, A. F. Pyesmany, Lawrence Wolff, P. C J Rogers, S. E. Siegel, R. J. Wells, J. D. Buckley, G. D. Hammond

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Amsacrine (AMSA) and cyclocytidine were studied as retrieval therapy in 122 pediatric patients with acute nonlymphoblastic leukemia (ANLL). Patients either failed to achieve sustained initial remissions or were in relapse. Induction therapy consisted of intravenous (IV) AMSA (75 mg/m2) from days 1 to 5 and subcutaneous cyclocytidine (600 mg/m2) from days 1 to 7. Maintenance therapy consisted of IV etoposide (VP-16) (100 mg/m2) for 5 days and IV AMSA (100 mg/m2) on day 1. Of 122 patients, 109 were evaluable. There were 13 early deaths. Ninety-six patients received adequate therapy defined as completion of two courses of therapy. Of these 96 patients, 52 achieved complete remission. Fifteen of 33 patients who failed initial induction achieved complete remission. Eighteen of 39 patients who were resistant to anthracyclines had complete responses. There was no direct evidence of AMSA-induced cardiotoxicity. Remission duration was 28 days to 3 or more years (median, 98 days). AMSA and cyclocytidine were effective retrieval therapy for patients who were in relapse or unresponsive to frontline therapy. Duration of remission was short (median, 98 days).

Original languageEnglish (US)
Pages (from-to)2235-2240
Number of pages6
JournalCancer
Volume67
Issue number9
Publication statusPublished - 1991

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Miller, L. P., Pyesmany, A. F., Wolff, L., Rogers, P. C. J., Siegel, S. E., Wells, R. J., ... Hammond, G. D. (1991). Succesful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group. Cancer, 67(9), 2235-2240.